首页> 外文期刊>Intelligence: A Multidisciplinary Journal >Pembrolizumab in combination with carboplatin versus carboplatin alone in breast cancer patients with chest wall disease: Translational Breast Cancer Research Consortium (TBCRC) 44 trial

【24h】

Pembrolizumab in combination with carboplatin versus carboplatin alone in breast cancer patients with chest wall disease: Translational Breast Cancer Research Consortium (TBCRC) 44 trial

机译：Pembrolizumab与Carboplatin与Carboplatin组合单独在乳腺癌患者胸壁病：翻译乳腺癌研究联盟（TBCRC）44试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal》 |2020年第2020期|共2页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学;
关键词

相似文献

外文文献
中文文献
专利

1. Pembrolizumab in combination with carboplatin versus carboplatin alone in breast cancer patients with chest wall disease: Translational Breast Cancer Research Consortium (TBCRC) 44 trial [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：Pembrolizumab与Carboplatin与Carboplatin组合单独在乳腺癌患者胸壁病：翻译乳腺癌研究联盟（TBCRC）44试验
2. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial [J] . Yardley D. A., Coleman R., Conte P., Annals of oncology: official journal of the European Society for Medical Oncology . 2018,第8期

机译：NAB-PACLITAXEL加上卡铂或吉西他滨与GEMCITABINE PLUS CARBOPLATIN作为三重阴性转移性乳腺癌患者的一线治疗：TNACITY试验结果
3. Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial [J] . Denise A. Yardley, Adam Brufsky, Robert E. Coleman, Trials . 2016,第1期

机译：错误至：'II / III期每周Nab-Paclitaxel Plus Gemcitabine或Carboplatin与吉西他滨/ carboplatin作为转移性三阴性乳腺癌患者的一线治疗（TNacity研究）：用于随机对照试验的研究方案
4. Breast Cancer Cells Response to the Antineoplastic Agents Cisplatin, Carboplatin, and Doxorubicin at the mRNA Expression Levels of Distinct Apoptosis-Related Genes, Including the New Member, BCL2L12 [C] . HELLINIDA THOMADAKI, ANDREAS SCORILAS Meeting on Cell Signaling World: Signal Transduction Pathways as Therapeutic Targets . 2007

机译：在不同凋亡相关基因（包括新成员BCL2L12）的mRNA表达水平上，乳腺癌细胞对抗肿瘤药顺铂，卡铂和阿霉素的反应
5. Understanding the Biology of Triple Negative Breast Cancer and Breast Cancer Stem Cells in Patients of Diverse Ethnicities [D] . Jiagge, Evelyn Mawunyo 2017

机译：了解不同种族患者的三阴性乳腺癌和乳腺癌干细胞生物学
6. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases [O] . Rachel A. Freedman, Rebecca S. Gelman, Jeffrey S. Wefel, -1

机译：转化型乳腺癌研究联合会（TBCRC）022：Neratinib用于人类表皮生长因子受体2阳性乳腺癌和脑转移患者的II期试验
7. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases [O] . Rachel A. Freedman, Rebecca S. Gelman, Jeffrey S. Wefel, 2016

机译：翻译乳腺癌研究联盟（TBCRC）022：人体表皮生长因子受体2阳性乳腺癌和脑转移患者的Neratinib的II期试验

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号